The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis

Thomas Reiberger, Thomas Reiberger

Abstract

Patients with compensated advanced chronic liver disease who develop clinically significant portal hypertension (CSPH) are at high risk for hepatic decompensation and mortality if left untreated. Liver biopsy and hepatic venous pressure gradient (HVPG) measurements are the current gold standard procedures for determining fibrosis severity and diagnosing CSPH, respectively; however, both are invasive, limiting their use in clinical practice and larger trials of novel agents. As such, there is an unmet clinical need for reliable, validated, noninvasive measures to detect CSPH and to further assess portal hypertension (PH) severity. Alterations in the biomechanical properties of the liver or spleen in patients with cirrhosis can be quantified by tissue elastography, which examines the elastic behavior of tissue after a force has been applied. A variety of methods are available, including magnetic resonance elastography, shear-wave elastography, and the most thoroughly investigated measure, vibration-controlled transient elastography. Liver stiffness (LS) and spleen stiffness (SS) measurements offer valuable alternatives to detect and monitor CSPH. Both LS and SS correlate well with HVPG, with thresholds of LS >20-25 kPa and SS >40-45 kPa indicating a high likelihood of CSPH. Because SS is a direct and dynamic surrogate of portal pressure, it has the potential to monitor PH severity and assess PH improvement as a surrogate marker for clinical outcomes. Importantly, SS seems to be superior to LS for monitoring treatment response in clinical trials focusing on reducing PH.

© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

Figures

FIG. 1
FIG. 1
Measurement of HVPG. HVPG is measured by retrograde insertion of a balloon‐tipped central vein catheter into a main hepatic vein. HVPG represents the difference between the occluded hepatic sinusoidal capillary network (wedged hepatic venous) pressure and the free hepatic venous (systemic) pressure. Abbreviations: FHVP, free hepatic venous pressure; IVCP, inferior vena cava pressure; RAP, right atrium pressure; WHVP, wedged hepatic venous pressure.
FIG. 2
FIG. 2
Techniques for identifying CSPH. Multiple screening techniques can be used to identify patients at high risk for progression to decompensated cirrhosis, with various cut‐off values to signify the presence of CSPH. Abbreviations: LSM, liver stiffness measurement; SSM, spleen stiffness measurement.

References

    1. GBD 2017 Cirrhosis Collaborators . The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245‐266.
    1. Estes C, Anstee QM, Arias‐Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016‐2030. J Hepatol 2018;69:896‐904.
    1. Axley P, Ahmed Z, Arora S, Haas A, Kuo Y‐F, Kamath PS, et al. NASH is the most rapidly growing etiology for acute‐on‐chronic liver failure‐related hospitalization and disease burden in the United States: a population‐based study. Liver Transpl 2019;25:695‐705.
    1. Garcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2017;65:310‐335. Erratum in: Hepatology 2017;66:304.
    1. D'Amico G, Garcia‐Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217‐231.
    1. Ripoll C, Groszmann R, Garcia–Tsao G, Grace N, Burroughs A, Planas R, et al.; Portal Hypertension Collaborative Group . Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 2007;133:481‐488.
    1. de Franchis R; Baveno VI Faculty . Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63:743‐752.
    1. Roccarina D, Rosselli M, Genesca J, Tsochatzis EA. Elastography methods for the non‐invasive assessment of portal hypertension. Expert Rev Gastroenterol Hepatol 2018;12:155‐164.
    1. Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. Mayo Clin Proc 2019;94:714‐726.
    1. Groszmann RJ, Garcia‐Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al.; Portal Hypertension Collaborative Group . Beta‐blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254‐2261.
    1. Ravaioli F, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, et al. Spleen stiffness mirrors changes in portal hypertension after successful interferon‐free therapy in chronic‐hepatitis C virus patients. World J Hepatol 2018;10:731‐742.
    1. Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 2019;70:1913‐1927.
    1. Zipprich A, Garcia‐Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int 2012;32:1407‐1414.
    1. Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, et al. Prioritization of therapeutic targets and trial design in cirrhotic portal hypertension. Hepatology 2019;69:1287‐1299.
    1. Villanueva C, Albillos A, Genescà J, Garcia‐Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double‐blind, placebo‐controlled, multicentre trial. Lancet 2019;393:1597‐1608. Erratum in: Lancet 2019;393:2492.
    1. Turco L, Villanueva C, La Mura V, García‐Pagán JC, Reiberger T, Genescà J, et al. Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta‐analysis. Clin Gastroenterol Hepatol 2020;18:313‐327.e316.
    1. European Association for the Study of the Liver . EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406‐460.
    1. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med 2016;375:767‐777.
    1. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER) . Nonalcoholic steatohepatitis with compensated cirrhosis: developing drugs for treatment. Guidance for industry. . Published June 2019. Accessed October 2020.
    1. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) . Reflection paper on regulatory requirements for the development of medicinal products for chronic non‐infectious liver diseases (PBC, PSC, NASH). . Published November 15, 2018. Accessed October 2020.
    1. Paton A, Reynolds TB, Sherlock S. Assessment of portal venous hypertension by catheterisation of hepatic vein. Lancet 1953;1:918‐921.
    1. Suk KT. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin Mol Hepatol 2014;20:6‐14.
    1. Libânio D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. World J Gastroenterol 2017;23:4669‐4674.
    1. European Association for the Study of Liver . EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012;57:399‐420.
    1. Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non‐invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) 2017;5:79‐89.
    1. Kalambokis G, Manousou P, Vibhakorn S, Marelli L, Cholongitas E, Senzolo M, et al. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications–a systematic review. J Hepatol 2007;47:284‐294.
    1. Reiberger T, Schwabl P, Trauner M, Peck‐Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp 2020;160:e58819.
    1. Colecchia A, Montrone L, Scaioli E, Bacchi–Reggiani ML, Colli A, Casazza G, et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV‐related cirrhosis. Gastroenterology 2012;143:646‐654.
    1. Leeming DJ, Karsdal MA, Byrjalsen I, Bendtsen F, Trebicka J, Nielsen MJ, et al. Novel serological neo‐epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther 2013;38:1086‐1096.
    1. Berzigotti A, Seijo S, Arena U, Abraldes JG, Vizzutti F, García–Pagán JC, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 2013;144:102‐111.e101.
    1. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012;56:1439‐1447.
    1. La Mura V, Reverter JC, Flores‐Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011;60:1133‐1138.
    1. Maieron A, Salzl P, Peck‐Radosavljevic M, Trauner M, Hametner S, Schöfl R, et al. Von Willebrand Factor as a new marker for non‐invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014;39:331‐338.
    1. Hametner S, Ferlitsch A, Ferlitsch M, Etschmaier A, Schöfl R, Ziachehabi A, et al. The VITRO score (von Willebrand factor antigen/thrombocyte ratio) as a new marker for clinically significant portal hypertension in comparison to other non‐invasive parameters of fibrosis including ELF test. PLoS One 2016;11:e0149230.
    1. Schwarzer R, Reiberger T, Mandorfer M, Kivaranovic D, Hametner S, Hametner S, et al. The von Willebrand factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. J Gastroenterol 2020;55:533‐542.
    1. Thabut D, Imbert‐bismut F, Cazals‐hatem D, Messous D, Muntenau M, Valla DC, et al. Relationship between the Fibrotest and portal hypertension in patients with liver disease. Aliment Pharmacol Ther 2007;26:359‐368.
    1. Verma V, Sarin SK, Sharma P, Kumar A. Correlation of aspartate aminotransferase/platelet ratio index with hepatic venous pressure gradient in cirrhosis. United European Gastroenterol J 2014;2:226‐231.
    1. Kirnake V, Arora A, Sharma P, Goyal M, Chawlani R, Toshniwal J, et al. Non‐invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis. Indian J Gastroenterol 2018;37:335‐341.
    1. Cho EJ, Kim MY, Lee J‐H, Lee IY, Lim YL, Choi DH, et al. Diagnostic and prognostic values of noninvasive predictors of portal hypertension in patients with alcoholic cirrhosis. PLoS One 2015;10:e0133935.
    1. Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Cecinato P, Turco L, et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis. Hepatology 2014;59:643‐650.
    1. Procopet B, Cristea VM, Robic MA, Grigorescu M, Agachi PS, Metivier S, et al. Serum tests, liver stiffness and artificial neural networks for diagnosing cirrhosis and portal hypertension. Dig Liver Dis 2015;47:411‐416.
    1. Simbrunner B, Marculescu R, Scheiner B, Schwabl P, Bucsics T, Stadlmann A, et al. Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver Int 2020;40:1713‐1724.
    1. Lisotti A, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child‐Pugh A cirrhosis and portal hypertension. Liver Int 2016;36:1313‐1321.
    1. Iranmanesh P, Vazquez O, Terraz S, Majno P, Spahr L, Poncet A, et al. Accurate computed tomography‐based portal pressure assessment in patients with hepatocellular carcinoma. J Hepatol 2014;60:969‐974.
    1. Qi X, An W, Liu F, Qi R, Wang L, Liu Y, et al. Virtual hepatic venous pressure gradient with CT angiography (CHESS 1601): a prospective multicenter study for the noninvasive diagnosis of portal hypertension. Radiology 2019;290:370‐377.
    1. Liu F, Ning Z, Liu Y, Liu D, Tian J, Luo H, et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study. EBioMedicine 2018;36:151‐158.
    1. Sartoris R, Rautou P‐E, Elkrief L, Pollorsi G, Durand F, Valla D, et al. Quantification of liver surface nodularity at CT: utility for detection of portal hypertension. Radiology 2018;289:698‐707.
    1. Mandorfer M, Hernández‐Gea V, García‐Pagán JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis 2020;40:240‐255.
    1. Ravaioli F, Montagnani M, Lisotti A, Festi D, Mazzella G, Azzaroli F. Noninvasive assessment of portal hypertension in advanced chronic liver disease: an update. Gastroenterol Res Pract 2018;2018:4202091.
    1. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis. Hepatology 2007;45:1290‐1297.
    1. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012;56:696‐703.
    1. Augustin S, Millán L, González A, Martell M, Gelabert A, Segarra A, et al. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: a prospective study. J Hepatol 2014;60:561‐569.
    1. European Association for the Study of the Liver; Clinical Practice Guideline Panel; Chair; EASL Governing Board representative; Panel members . EASL Clinical Practice Guidelines on non‐invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol 2021;75:659‐689.
    1. Shi K‐Q, Fan Y‐C, Pan Z‐Z, Lin X‐F, Liu W‐Y, Chen Y‐P, et al. Transient elastography: a meta‐analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver Int 2013;33:62‐71.
    1. You M‐W, Kim KW, Pyo J, Huh J, Kim HJ, Lee SJ, et al. A meta‐analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension. Ultrasound Med Biol 2017;43:59‐68.
    1. Robic MA, Procopet B, Métivier S, Péron JM, Selves J, Vinel JP, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011;55:1017‐1024.
    1. Attia D, Schoenemeier B, Rodt T, Negm A, Lenzen H, Lankisch T, et al. Evaluation of liver and spleen stiffness with acoustic radiation force impulse quantification elastography for diagnosing clinically significant portal hypertension. Ultraschall Med 2015;36:603‐610.
    1. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al.; Anticipate Investigators . Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology 2016;64:2173‐2184. Erratum in: Hepatology 2017;66:304‐305.
    1. Galizzi HO, Couto CA, Taranto DOL, Araújo SIO, Vilela EG. Accuracy of non‐invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100229.
    1. Sousa M, Fernandes S, Proença L, Silva AP, Leite S, Silva J, et al. The Baveno VI criteria for predicting esophageal varices: validation in real life practice. Rev Esp Enferm Dig 2017;109:704‐707.
    1. Moctezuma‐Velazquez C, Saffioti F, Tasayco‐Huaman S, Casu S, Mason A, Roccarina D, et al. Non‐invasive prediction of high‐risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis. Am J Gastroenterol 2019;114:446‐452.
    1. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol 2021;116:723‐732.
    1. Wong GL, Chan HL, Choi PC, Chan AW, Lo AO, Chim AM, et al. Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013;11:295‐302.e291‐293.
    1. Wong V‐S, Irles M, Wong G‐H, Shili S, Chan A‐H, Merrouche W, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non‐alcoholic fatty liver disease. Gut 2019;68:2057‐2064.
    1. Nedredal GI, Yin M, McKenzie T, Lillegard J, Luebke‐Wheeler J, Talwalkar J, et al. Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging 2011;34:79‐87.
    1. Mejias M, Garcia‐Pras E, Gallego J, Méndez R, Bosch J, Fernandez M. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol 2010;52:529‐539.
    1. Bolognesi M, Di Pascoli M, Verardo A, Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014;20:2555‐2563.
    1. Buechter M, Manka P, Theysohn JM, Reinboldt M, Canbay A, Kahraman A. Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. Dig Liver Dis 2018;50:54‐60.
    1. Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV‐related cirrhosis: a prospective study. J Hepatol 2014;60:1158‐1164.
    1. Song J, Huang J, Huang H, Liu S, Luo Y. Performance of spleen stiffness measurement in prediction of clinical significant portal hypertension: a meta‐analysis. Clin Res Hepatol Gastroenterol 2018;42:216‐226.
    1. Stefanescu H, Rusu C, Lupsor‐Platon M, Nicoara Farcau O, Fischer P, Grigoras C, et al. Liver stiffness assessed by ultrasound shear wave elastography from General Electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease. Ultraschall Med 2020;41:526‐533.
    1. Colecchia A, Ravaioli F, Marasco G, Colli A, Dajti E, Di Biase AR, et al. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high‐risk varices in advanced chronic liver disease. J Hepatol 2018;69:308‐317.
    1. Dajti E, Marasco G, Ravaioli F, Alemanni LV, Rossini B, Colecchia L, et al. The role of liver and spleen elastography in advanced chronic liver disease. Minerva Gastroenterol (Torino) 2021;67:151‐163.
    1. Talwalkar JA, Yin M, Venkatesh S, Rossman PJ, Grimm RC, Manduca A, et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. AJR Am J Roentgenol 2009;193:122‐127.
    1. Fierbinteanu‐Braticevici C, Tribus L, Peagu R, Petrisor A, Baicus C, Cretoiu D, et al. Spleen stiffness as predictor of esophageal varices in cirrhosis of different etiologies. Sci Rep 2019;9:16190.
    1. Kim HY, So YH, Kim W, Ahn D‐W, Jung YJ, Woo H, et al. Non‐invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412‐422.
    1. Ma X, Wang LE, Wu H, Feng Y, Han X, Bu H, et al. Spleen stiffness is superior to liver stiffness for predicting esophageal varices in chronic liver disease: a meta‐analysis. PLoS One 2016;11:e0165786.
    1. Rosołowski M, Hartleb M, Marek T, Milewski J, Linke K, Wallner G, et al. Therapeutic and prophylactic management of bleeding from oesophageal and gastric varices ‐ recommendations of the Working Group of the National Consultant for Gastroenterology. Prz Gastroenterol 2014;9:63‐68.
    1. Jansen C, Möller P, Meyer C, Kolbe CC, Bogs C, Pohlmann A, et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology 2018;67:1472‐1484.
    1. Königshofer P. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology 2021. 10.1002/hep.32220.
    1. Marasco G, Dajti E, Ravaioli F, Alemanni LV, Capuano F, Gjini K, et al. Spleen stiffness measurement for assessing the response to β‐blockers therapy for high‐risk esophageal varices patients. Hepatol Int 2020;14:850‐857.
    1. Kim HP, Moon AM, Dellon ES. Noninvasively predicting hemodynamic response to carvedilol in cirrhotic patients with varices: you have some ex‐spleening to do. Gastroenterology 2019;156:2347‐2349.
    1. Salzl P, Reiberger T, Ferlitsch M, Payer B, Schwengerer B, Trauner M, et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index. Ultraschall Med 2014;35:528‐533.
    1. Elkrief L, Rautou P‐E, Ronot M, Lambert S, Dioguardi Burgio M, Francoz C, et al. Prospective comparison of spleen and liver stiffness by using shear‐wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology 2015;275:589‐598.
    1. Thiele M, Hugger MB, Kim Y, Rautou P‐E, Elkrief L, Jansen C, et al. 2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: an individual patient data meta‐analysis. Liver Int 2020;40:1435‐1446.
    1. Procopet B, Berzigotti A, Abraldes JG, Turon F, Hernandez‐Gea V, García‐Pagán JC, et al. Real‐time shear‐wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. J Hepatol 2015;62:1068‐1075.
    1. Trebicka J, Gu W, de Ledinghen V, Aubé C, Krag A, Praktiknjo M, et al. Two‐dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut 2021; 10.1136/gutjnl-2020-323419.
    1. Wong GLH, Kwok R, Hui AJ, Tse Y‐K, Ho K‐T, Lo AOS, et al. A new screening strategy for varices by liver and spleen stiffness measurement (LSSM) in cirrhotic patients: a randomized trial. Liver Int 2018;38:636‐644.
    1. Wong G‐H, Liang LY, Kwok R, Hui AJ, Tse Y‐K, Chan H‐Y, et al. Low risk of variceal bleeding in patients with cirrhosis after variceal screening stratified by liver/spleen stiffness. Hepatology 2019;70:971‐981.
    1. Jansen C, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen J, et al. Algorithm to rule out clinically significant portal hypertension combining shear‐wave elastography of liver and spleen: a prospective multicentre study. Gut 2016;65:1057‐1058.
    1. Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Bernuzzi S, Salvaneschi L, et al. Ultrasound point shear wave elastography assessment of liver and spleen stiffness: effect of training on repeatability of measurements. Eur Radiol 2014;24:1283‐1289.
    1. Castéra L, Foucher J, Bernard P‐H, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5‐year prospective study of 13,369 examinations. Hepatology 2010;51:828‐835.
    1. Ferraioli G, Barr RG. Ultrasound liver elastography beyond liver fibrosis assessment. World J Gastroenterol 2020;26:3413‐3420.
    1. DiPaola FW, Schumacher KR, Goldberg CS, Friedland‐Little J, Parameswaran A, Dillman JR. Effect of Fontan operation on liver stiffness in children with single ventricle physiology. Eur Radiol 2017;27:2434‐2442.
    1. Dietrich C, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (short version). Ultraschall Med 2017;38:377‐394.
    1. Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008;48:1718‐1723.
    1. Berzigotti A, De Gottardi A, Vukotic R, Siramolpiwat S, Abraldes JG, García‐Pagan JC, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One 2013;8:e58742.
    1. Alvarez D, Orozco F, Mella JM, Anders M, Antinucci F, Mastai R. Meal ingestion markedly increases liver stiffness suggesting the need for liver stiffness determination in fasting conditions. Gastroenterol Hepatol 2015;38:431‐435.
    1. Kjærgaard M, Thiele M, Jansen C, Stæhr Madsen B, Görtzen J, Strassburg C, et al. High risk of misinterpreting liver and spleen stiffness using 2D shear‐wave and transient elastography after a moderate or high calorie meal. PLoS One 2017;12:e0173992.
    1. Yoo J‐J, Seo YS, Kim YS, Jeong SW, Jang JY, Suh SJ, et al. The influence of histologic inflammation on the improvement of liver stiffness values over 1 and 3 years. J Clin Med 2019;8:2065.
    1. Mueller S, Englert S, Seitz HK, Badea RI, Erhardt A, Bozaari B, et al. Inflammation‐adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease. Liver Int 2015;35:2514‐2521.
    1. Janik MK, Kruk B, Szczepankiewicz B, Kostrzewa K, Raszeja‐Wyszomirska J, Górnicka B, et al. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Liver Int 2021;41:348‐356.
    1. Giuffrè M, Fouraki S, Campigotto M, Colombo A, Visintin A, Buonocore MR, et al. Alanine aminotransferase and spleno‐portal dynamics affect spleen stiffness measured by point shear‐wave elastography in patients with chronic hepatitis C in the absence of significant liver fibrosis. J Ultrasound 2021;24:67‐73.
    1. Wang H, Wen B, Chang X, Wu Q, Wen W, Zhou F, et al. Baveno VI criteria and spleen stiffness measurement rule out high‐risk varices in virally suppressed HBV‐related cirrhosis. J Hepatol 2021;74:584‐592.
    1. Bureau C, Metivier S, Peron JM, Selves J, Robic MA, Gourraud PA, et al. Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther 2008;27:1261‐1268.
    1. Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne‐carrie N, Kazemi F, et al. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol‐related cirrhosis. Aliment Pharmacol Ther 2008;28:1102‐1110.
    1. Sánchez‐Conde M, Montes‐Ramírez ML, Miralles P, Castro Alvarez JM, Bellón JM, Ramírez M, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus‐coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010;17:280‐286.
    1. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography–a large single center experience. Wien Klin Wochenschr 2012;124:395‐402.
    1. Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012;56:103‐108.
    1. Hong WK, Kim MY, Baik SK, Shin SY, Kim JM, Kang YS, et al. The usefulness of non‐invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Clin Mol Hepatol 2013;19:370‐375.
    1. Sharma P, Kirnake V, Tyagi P, Bansal N, Singla V, Kumar A, et al. Spleen stiffness in patients with cirrhosis in predicting esophageal varices. Am J Gastroenterol 2013;108:1101‐1107.
    1. Kim TY, Jeong WK, Sohn JH, Kim J, Kim MY, Kim Y. Evaluation of portal hypertension by real‐time shear wave elastography in cirrhotic patients. Liver Int 2015;35:2416‐2424.
    1. Schwabl P, Bota S, Salzl P, Mandorfer M, Payer BA, Ferlitsch A, et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Int 2015;35:381‐390.
    1. Jansen C, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen J, et al. Shear‐wave elastography of the liver and spleen identifies clinically significant portal hypertension: a prospective multicentre study. Liver Int 2017;37:396‐405.
    1. Souhami A, Sartoris R, Rautou P‐E, Cauchy F, Bouattour M, Durand F, et al. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Rep 2020;2:100147.
    1. Kim HY, Jin EH, Kim W, Lee JY, Woo H, Oh S, et al. The role of spleen stiffness in determining the severity and bleeding risk of esophageal varices in cirrhotic patients. Medicine (Baltimore) 2015;94:e1031.
    1. Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Bacchi Reggiani ML, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. J Hepatol 2019;70:440‐448.
    1. Stefanescu H, Marasco G, Calès P, Fraquelli M, Rosselli M, Ganne‐Carriè N, et al. A novel spleen‐dedicated stiffness measurement by FibroScan® improves the screening of high‐risk oesophageal varices. Liver Int 2020;40:175‐185.
    1. Cho YS, Kim Y, Sohn JH. Application of supersonic shear imaging to the Baveno VI criteria and a combination model with spleen stiffness measurement to rule out high‐risk varices in compensated advanced chronic liver disease. Ultraschall Med 2020; 10.1055/a-1168-6271.
    1. Dajti E, Marasco G, Ravaioli F, Colecchia L, Ferrarese A, Festi D, et al. Risk of hepatocellular carcinoma after HCV eradication: determining the role of portal hypertension by measuring spleen stiffness. JHEP Rep 2021;3:100289.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe